ALX Oncology Holdings

Filter

År

Typ

Språk

Rensa

2025-04-25 19:10:00 ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma 0,54 USD | -9,87%

2025-04-25 15:00:00 ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints 0,54 USD | -9,87%

2025-03-06 22:01:00 ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update 1,31 USD | +25,96%

2025-03-05 14:00:00 ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event 1,04 USD | +4,00%

2025-01-23 14:00:00 ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer 1,63 USD | -9,44%

2025-01-22 22:01:00 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules 1,80 USD | +9,09%

2025-01-22 14:00:00 ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors 1,80 USD | +9,09%

2025-01-21 23:00:00 ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI 1,65 USD | -5,17%

2024-12-18 14:00:00 ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium 1,84 USD | +2,79%

2024-12-12 14:00:00 ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 1,42 USD | -5,96%

2024-12-10 15:00:00 ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer 1,58 USD | -8,14%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

ALX Oncology Holdings

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden